{
  "ticker": "CADL",
  "company_name": "Candel Therapeutics, Inc.",
  "success": true,
  "trials": [
    {
      "nct_id": "NCT03576612",
      "title": "GMCI, Nivolumab, and Radiation Therapy in Treating Patients With Newly Diagnosed High-Grade Gliomas",
      "status": "COMPLETED",
      "phase": "PHASE1",
      "condition": "Glioma, Malignant",
      "start_date": "2018-02-27",
      "completion_date": "2023-06-30",
      "enrollment": 0,
      "sponsor": "Candel Therapeutics, Inc."
    },
    {
      "nct_id": "NCT00589875",
      "title": "Phase 2a Study of CAN-2409 With Standard Radiation Therapy for Malignant Glioma",
      "status": "COMPLETED",
      "phase": "PHASE2",
      "condition": "Malignant Glioma, Glioblastoma Multiforme, Anaplastic Astrocytoma, High Grade Glioma",
      "start_date": "2007-03",
      "completion_date": "2016-08",
      "enrollment": 0,
      "sponsor": "Candel Therapeutics, Inc."
    },
    {
      "nct_id": "NCT03131037",
      "title": "Intratumoral Gene Mediated Cytotoxic Immunotherapy in Patients With Resectable Non-Small Cell Lung Cancer",
      "status": "COMPLETED",
      "phase": "PHASE1",
      "condition": "Lung Cancer",
      "start_date": "2017-05-04",
      "completion_date": "2023-09-20",
      "enrollment": 0,
      "sponsor": "Candel Therapeutics, Inc."
    },
    {
      "nct_id": "NCT00751270",
      "title": "Phase 1b Study of AdV-tk + Valacyclovir Combined With Radiation Therapy for Malignant Gliomas",
      "status": "COMPLETED",
      "phase": "PHASE1",
      "condition": "Malignant Glioma, Glioblastoma Multiforme, Anaplastic Astrocytoma",
      "start_date": "2005-11",
      "completion_date": "2011-01",
      "enrollment": 0,
      "sponsor": "Candel Therapeutics, Inc."
    },
    {
      "nct_id": "NCT01997190",
      "title": "Intrapleural AdV-tk Therapy in Patients With Malignant Pleural Effusion",
      "status": "COMPLETED",
      "phase": "PHASE1",
      "condition": "Malignant Pleural Effusion, Lung Cancer, Mesothelioma, Breast Cancer, Ovarian Cancer",
      "start_date": "2013-10",
      "completion_date": "2018-02",
      "enrollment": 0,
      "sponsor": "Candel Therapeutics, Inc."
    },
    {
      "nct_id": "NCT00634231",
      "title": "A Phase I Study of AdV-tk + Prodrug Therapy in Combination With Radiation Therapy for Pediatric Brain Tumors",
      "status": "COMPLETED",
      "phase": "PHASE1",
      "condition": "Malignant Glioma, Recurrent Ependymoma",
      "start_date": "2010-10",
      "completion_date": "2021-06",
      "enrollment": 0,
      "sponsor": "Candel Therapeutics, Inc."
    },
    {
      "nct_id": "NCT07332000",
      "title": "A Biomarker Study in Men With Localized Prostate Cancer Treated With Aglatimagene Besadenovec",
      "status": "RECRUITING",
      "phase": "PHASE2",
      "condition": "Prostate Cancer Patients Treated by Radiotherapy",
      "start_date": "2026-01",
      "completion_date": "2026-06",
      "enrollment": 0,
      "sponsor": "Candel Therapeutics, Inc."
    },
    {
      "nct_id": "NCT02768363",
      "title": "Randomized Controlled Trial of CAN-2409 Immunotherapy During Active Surveillance for Prostate Cancer (ULYSSES)",
      "status": "ACTIVE_NOT_RECRUITING",
      "phase": "PHASE2",
      "condition": "Prostate Cancer",
      "start_date": "2016-05",
      "completion_date": "2026-12",
      "enrollment": 0,
      "sponsor": "Candel Therapeutics, Inc."
    },
    {
      "nct_id": "NCT04495153",
      "title": "CAN-2409 Plus Prodrug With Standard of Care Immune Checkpoint Inhibitor for Stage III/IV NSCLC",
      "status": "ACTIVE_NOT_RECRUITING",
      "phase": "PHASE2",
      "condition": "Non Small Cell Lung Cancer",
      "start_date": "2020-10-13",
      "completion_date": "2026-12",
      "enrollment": 0,
      "sponsor": "Candel Therapeutics, Inc."
    },
    {
      "nct_id": "NCT02446093",
      "title": "Neoadjuvant CAN-2409 in Combination With Chemoradiation or SBRT for Borderline Resectable Pancreatic Adenocarcinoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "phase": "PHASE2",
      "condition": "Borderline Resectable Pancreatic Adenocarcinoma",
      "start_date": "2015-10",
      "completion_date": "2026-07",
      "enrollment": 0,
      "sponsor": "Candel Therapeutics, Inc."
    }
  ],
  "summary": {
    "total_trials": 13,
    "by_phase": {
      "PHASE1": 7,
      "PHASE2": 5,
      "PHASE3": 1
    },
    "by_status": {
      "COMPLETED": 7,
      "RECRUITING": 2,
      "ACTIVE_NOT_RECRUITING": 4
    },
    "active_trials": 6,
    "completed_trials": 7,
    "conditions": [
      "Borderline Resectable Pancreatic Adenocarcinoma",
      "Glioma, Malignant",
      "Lung Cancer",
      "Malignant Glioma of Brain, Astrocytoma, Malignant Astrocytoma, Oligodendroglioma, Anaplastic Oligodendroglioma of Brain (Diagnosis), Mixed Oligo-Astrocytoma, Ependymoma, Ganglioglioma, Pylocytic/Pylomyxoid Astrocytoma, Brain Tumor, Glioma, Brain Cancer, Glioblastoma, Glioblastoma Multiforme",
      "Malignant Glioma, Glioblastoma Multiforme, Anaplastic Astrocytoma",
      "Malignant Glioma, Glioblastoma Multiforme, Anaplastic Astrocytoma, High Grade Glioma",
      "Malignant Glioma, Recurrent Ependymoma",
      "Malignant Pleural Effusion, Lung Cancer, Mesothelioma, Breast Cancer, Ovarian Cancer",
      "Non Small Cell Lung Cancer",
      "Pancreatic Adenocarcinoma, Pancreatic Cancer",
      "Prostate Cancer",
      "Prostate Cancer Patients Treated by Radiotherapy"
    ],
    "lead_stage": "phase_3"
  },
  "provenance": {
    "source": "ClinicalTrials.gov API v2",
    "timestamp": "2026-01-29T12:17:17.744846",
    "search_query": "Candel Therapeutics, Inc.",
    "url": "https://clinicaltrials.gov/search?term=Candel+Therapeutics,+Inc."
  }
}